Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M.

BMJ. 1999 Mar 6;318(7184):633-8. Erratum in: BMJ 2001 Jun 16;322(7300):1456.

2.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(4):CD001191. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001191.

PMID:
11034705
3.

Rivastigmine for Alzheimer's disease.

Birks J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(2):CD001191. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD001191.

PMID:
10796621
4.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
5.

Rivastigmine for Alzheimer's disease.

Birks JS, Grimley Evans J.

Cochrane Database Syst Rev. 2015 Apr 10;(4):CD001191. doi: 10.1002/14651858.CD001191.pub3. Review.

PMID:
25858345
6.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;4:CD001191.

PMID:
19370562
7.

Metrifonate for Alzheimer's disease.

López-Arrieta JM, Schneider L.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003155. Review.

PMID:
16625573
8.

Rivastigmine. A review of its use in Alzheimer's disease.

Spencer CM, Noble S.

Drugs Aging. 1998 Nov;13(5):391-411. Review.

PMID:
9829166
9.

Rivastigmine for Alzheimer's disease.

Birks JS, Chong LY, Grimley Evans J.

Cochrane Database Syst Rev. 2015 Sep 22;9:CD001191. [Epub ahead of print] Review.

PMID:
26393402
10.

Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.

Desai A, Grossberg G.

Expert Opin Pharmacother. 2001 Apr;2(4):653-66. Review. Erratum in: Expert Opin Pharmacother 2001 May;2(5):907.

PMID:
11336614
11.

Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

Lamb HM, Goa KL.

Pharmacoeconomics. 2001;19(3):303-18. Review.

PMID:
11303418
12.

Rivastigmine for vascular cognitive impairment.

Birks J, McGuinness B, Craig D.

Cochrane Database Syst Rev. 2013 May 31;(5):CD004744. doi: 10.1002/14651858.CD004744.pub3. Review.

PMID:
23728651
13.

Velnacrine for Alzheimer's disease.

Birks J, Wilcock GG.

Cochrane Database Syst Rev. 2004;(2):CD004748. Review.

PMID:
15106259
14.

Evidence-based pharmacotherapy of Alzheimer's disease.

Evans JG, Wilcock G, Birks J.

Int J Neuropsychopharmacol. 2004 Sep;7(3):351-69. Review.

PMID:
15228642
15.

The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients.

Potkin SG.

Int Psychogeriatr. 2002;14 Suppl 1:7-26. Review.

PMID:
12636178
16.

Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.

Frampton JE.

Drugs Aging. 2014 Aug;31(8):639-49. doi: 10.1007/s40266-014-0197-x. Review.

PMID:
24989628
17.

Rivastigmine for dementia in people with Down syndrome.

Mohan M, Bennett C, Carpenter PK.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007658. doi: 10.1002/14651858.CD007658. Review.

PMID:
19160344
18.

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR.

CMAJ. 2003 Sep 16;169(6):557-64. Review.

19.

Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial.

Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study Group..

Lancet Neurol. 2012 Oct;11(10):851-9. doi: 10.1016/S1474-4422(12)70206-5. Review.

PMID:
22959217
20.

Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors.

Leinonen A, Koponen M, Hartikainen S.

PLoS One. 2015 May 1;10(5):e0124500. doi: 10.1371/journal.pone.0124500. Review.

Supplemental Content

Support Center